Provided by Tiger Fintech (Singapore) Pte. Ltd.

NLS Pharmaceutics Ltd.

2.57
+0.06002.39%
Volume:159.14K
Turnover:408.22K
Market Cap:12.61M
PE:-0.39
High:2.65
Open:2.60
Low:2.47
Close:2.51
52wk High:7.44
52wk Low:1.30
Shares:4.91M
Float Shares:3.44M
Volume Ratio:0.79
T/O Rate:4.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5851
EPS(LYR):-12.7536
ROE:-862.92%
ROA:-111.41%
PB:-9.45
PE(LYR):-0.20

Loading ...

Company Profile

Company Name:
NLS Pharmaceutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
- -
Office Location:
The Circle 6,Zurich,Zurich,Switzerland
Zip Code:
8058
Fax:
41 44 512 21 51
Introduction:
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Directors

Name
Position
Ronen Twito
Executive Chairman and Chief Executive Officer
Eran Iohan
Independent Director
Liora Oren
Independent Director
Michel Revel
Director and Chief Scientific Officer
Olivier Samuel
Independent Director
Alexander Zwyer
Director
Tammy Galili
Director

Shareholders

Name
Position
Ronen Twito
Executive Chairman and Chief Executive Officer
Uri Ben Or
Chief Financial Officer
Ariel Revel
Director of Medical Affairs
Eric Konofal
Head of DOXA Program
Kfir Molakandov
Vice President of Research and Development
Michel Revel
Director and Chief Scientific Officer